Cannabinoids & Psychedelics Global leader in custom synthesis of active pharmaceutical ingredients including cannabinoids, psychedelics, and reference standards with multiple DMFs and GMP capabilities, presenting opportunities to supply APIs, intermediates, reference standards, and development support for pharma and biotech clients pursuing cannabinoid or psychedelic programs.

CDMO Capabilities Full service preclinical to commercial API development and manufacturing in FDA-inspected GMP suites, including HPAPI and environmentally sensitive APIs, enabling upsell to clients needing scalable synthesis, regulatory support, and niche drug substance production.

Reference Standards Stocking over 250 reference standards and worldwide shipping to 30+ countries, offering a recurring revenue stream from analytical standards supply, method development, and qualification services to CROs, pharma, and research organizations.

Strategic Growth</tagline> Part of the Siegfried Group with ongoing global expansion and leadership changes in the parent company, signaling potential cross-sell opportunities to leverage broader CDMO network, financing, and manufacturing scale for joint opportunities in large global accounts.

Regulatory & Compliance Established DMFs and GMP manufacturing capabilities for regulated substances, including controlled cannabinoids and psychedelic APIs, enabling risk-managed engagements with pharma sponsors seeking compliant, auditable supply chains and regulatory readiness across IND/IMPD/NDA/ANDA pathways.